A Phase 2 interventional study of Retatrutide and Placebo in Overweight or Obesity, CKD and Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.
Among the 16 studies testing retatrutide in Obesity, this one is the 12th largest by enrollment, is one of 6 that started in 2023, is one of 3 in phase 2, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Hudson Biotech · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 146 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 392 across the 16 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 82nd largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 22 in phase 2, and was the 36th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
4 of the studies testing retatrutide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
| NCT07035093Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | 2027-09 |
| NCT07467447Hudson BiotechEffect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | 2027-03-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing retatrutide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 146 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have either
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received retatrutide administered subcutaneously once weekly for approximately 24 weeks. Treatment was initiated at 2 milligrams (mg) once weekly and escalated every 4 weeks to 4 mg, 6 mg, 9 mg, and 12 mg. The target maintenance dose was 12 mg once weekly. Participants who did not tolerate the 12 mg dose could remain on a maintenance dose of 4 mg, 6 mg, or 9 mg.
Drug: Retatrutide
Participants received placebo matched retatrutide administered subcutaneously once weekly for approximately 24 weeks. To maintain blinding, participants followed a sham dose-escalation schedule with changes in administered volume every 4 weeks to match the retatrutide dose-escalation schedule.
Drug: Placebo
Administered Subcutaneously
Also known as: LY3437943
Administered Subcutaneously
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24
Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 Body Surface Area (BSA)-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in milliliters per minute per 1.73 square meters (mL/min/1.73 m²). Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.
Time frame: Baseline, Week 24
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16
Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 16 BSA-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in mL/min/1.73 m².
Time frame: Baseline, Week 16
Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24
Urine Albumin-to-Creatinine ratio (UACR) was calculated by the central laboratory from urinary albumin and urinary creatinine measurements. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Baseline and postbaseline UACR values were log-transformed for analysis. Model estimates were back-transformed and reported as percent change from baseline. A negative value indicates a decrease from baseline. Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.
Time frame: Baseline, Week 24
Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24
Creatinine-corrected fractional excretion of sodium (FENa) was calculated as: FENa (%) = 100 × \[(serum creatinine × urine sodium) / (serum sodium × urine creatinine)\]. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 FENa minus the baseline FENa.
Time frame: Baseline, Week 24
Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24
Filtration fraction was calculated as non-BSA-indexed mGFR (mL/min) divided by renal plasma flow (mL/min). Renal plasma flow was calculated as MRI-measured renal blood flow × (1 - hematocrit). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 filtration fraction minus the baseline filtration fraction.
Time frame: Baseline, Week 24
Change From Baseline in Mean Arterial Flow (MAF) at Week 24
Mean arterial flow (MAF) was the bilateral mean blood flow in the renal arteries measured using phase-contrast magnetic resonance imaging (PC-MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 MAF minus the baseline MAF.
Time frame: Baseline, Week 24
Change From Baseline in Renal Artery Resistive Index (RARI) at Week 24
RARI is a dimensionless measure of resistance to renal arterial blood flow and was calculated from phase-contrast magnetic resonance imaging (PC-MRI) as: RARI= (peak systolic velocity \[PSV\]- end-diastolic velocity \[EDV\]) /PSV. RARI has a theoretical range of 0 to 1, with higher values generally representing a less favorable outcome. In general adult population, RARI values of 0.50 to 0.70 are typically considered normal, and values greater than 0.70 are generally considered elevated; however, these reference values are derived from Doppler ultrasound measurements, and MRI-based RARI values may differ and require further validation. LS mean was estimated using a MMRM including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as Week 24 RARI minus the baseline RARI.
Time frame: Baseline, Week 24
Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24
Peak systolic velocity (PSV) was the highest renal arterial blood flow velocity measured during systole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 PSV minus the baseline PSV.
Time frame: Baseline, Week 24
Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24
End-diastolic velocity (EDV) was the lowest renal arterial blood flow velocity measured during diastole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 EDV minus the baseline EDV.
Time frame: Baseline, Week 24
Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24
Total renal parenchyma volume was measured using magnetic resonance imaging by delineating the corresponding regions of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Total Renal Parenchyma Volume was calculated as: 100 × (Week 24 total renal parenchyma volume - baseline total renal parenchyma volume) / baseline total renal parenchyma volume.
Time frame: Baseline, Week 24
Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 24
Renal cortex volume was measured using magnetic resonance imaging by delineating the renal cortex region of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex Volume was calculated as: 100 × (Week 24 renal cortex volume - baseline renal cortex volume) / baseline renal cortex volume.
Time frame: Baseline, Week 24
Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24
Kidney parenchyma global perfusion was assessed as the mean renal blood flow per 100 g of kidney tissue measured by magnetic resonance imaging (MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Kidney Parenchyma Global Perfusion was calculated as: 100 × (Week 24 kidney parenchyma global perfusion - baseline kidney parenchyma global perfusion) / baseline kidney parenchyma global perfusion.
Time frame: Baseline, Week 24
Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 24
Renal cortex T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex T1 was calculated as: 100 × (Week 24 renal cortex T1 - baseline renal cortex T1) / baseline renal cortex T1.
Time frame: Baseline, Week 24
Percent Change From Baseline in Renal Medulla T1 (MRI) at Week 24
Renal medulla T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Medulla T1 was calculated as: 100 × (Week 24 renal medulla T1 - baseline renal medulla T1) / baseline renal medulla T1.
Time frame: Baseline, Week 24
Percent Change From Baseline in Renal Cortex R2* at Week 24
Renal cortex R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex R2\* was calculated as:100 × (Week 24 renal cortex R2\* - baseline renal cortex R2\*) / baseline renal cortex R2\*
Time frame: Baseline, Week 24
Percent Change From Baseline in Renal Medulla R2* at Week 24
Renal medulla R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction, with an unstructured covariance matrix. Percent change from baseline in Renal Medulla R2\* was calculated as:100 × (Week 24 renal medulla R2\* - baseline renal medulla R2\*) / baseline renal medulla R2\*.
Time frame: Baseline, Week 24
Percent Change From Baseline in Body Weight at Week 24
Body weight was measured in kilograms using a calibrated electronic scale. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline was calculated as: 100 × (Week 24 body weight - baseline body weight) / baseline body weight. A negative value indicates a decrease in body weight.
Time frame: Baseline, Week 24
Percent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24
Twenty-four-hour urinary albumin excretion (UAE) was derived from the 24-hour urine collection. Percent change from baseline at Week 24 was calculated relative to the baseline UAE value and was reported as %. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures on the log-transformed ratio to baseline, with log-transformed baseline value, treatment, and joint levels of stratification factors included as covariates. LS mean estimates and treatment comparisons were backtransformed and expressed as percent change from baseline. As pre-specified in the Statistical Analysis Plan, missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.
Time frame: Baseline, Week 24
Change From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24
Twenty-four-hour urinary electrolyte excretion was derived from the 24-hour urine collection. Change from baseline was calculated as the Week 24 value minus the baseline value. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures, with baseline, treatment, and joint levels of stratification factors included as covariates. As pre-specified in Statistical Analysis Plan, Missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.
Time frame: Baseline, Week 24
| Milestone | Placebo | Retatrutide |
|---|---|---|
| Started | 71 | 75 |
| Received at least one dose of study drug | 69 | 73 |
| Completed | 60 | 58 |
| Not completed | 11 | 17 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol deviation | 1 | 2 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Iodinated contrast allergy | 0 | 1 |
| Withdrew: Noncompliance with study procedures | 0 | 1 |
| Withdrew: Participant unavailable due to extended travel | 1 | 0 |
| Withdrew: Inability to obtain intravenous (iv) access | 1 | 0 |
Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 Body Surface Area (BSA)-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in milliliters per minute per 1.73 square meters (mL/min/1.73 m²). Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.
| mL/min/1.73 m² | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24 | -0.19 ± 2.690 | -1.62 ± 2.820 |
Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 16 BSA-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in mL/min/1.73 m².
| mL/min/1.73 m² | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16 | -4.08 ± 1.923 | -4.34 ± 1.993 |
Urine Albumin-to-Creatinine ratio (UACR) was calculated by the central laboratory from urinary albumin and urinary creatinine measurements. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Baseline and postbaseline UACR values were log-transformed for analysis. Model estimates were back-transformed and reported as percent change from baseline. A negative value indicates a decrease from baseline. Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24 | -8.75 ± 17.575 | -53.65 ± 8.267 |
Creatinine-corrected fractional excretion of sodium (FENa) was calculated as: FENa (%) = 100 × \[(serum creatinine × urine sodium) / (serum sodium × urine creatinine)\]. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 FENa minus the baseline FENa.
| Percentage of FENa | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24 | 0.06 ± 0.075 | -0.23 ± 0.082 |
Filtration fraction was calculated as non-BSA-indexed mGFR (mL/min) divided by renal plasma flow (mL/min). Renal plasma flow was calculated as MRI-measured renal blood flow × (1 - hematocrit). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 filtration fraction minus the baseline filtration fraction.
| Unitless | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24 | -0.01 ± 0.008 | -0.02 ± 0.008 |
Mean arterial flow (MAF) was the bilateral mean blood flow in the renal arteries measured using phase-contrast magnetic resonance imaging (PC-MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 MAF minus the baseline MAF.
| Milliliter/Minute (mL/min) | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Mean Arterial Flow (MAF) at Week 24 | 0.6 ± 22.37 | -6.9 ± 22.25 |
RARI is a dimensionless measure of resistance to renal arterial blood flow and was calculated from phase-contrast magnetic resonance imaging (PC-MRI) as: RARI= (peak systolic velocity \[PSV\]- end-diastolic velocity \[EDV\]) /PSV. RARI has a theoretical range of 0 to 1, with higher values generally representing a less favorable outcome. In general adult population, RARI values of 0.50 to 0.70 are typically considered normal, and values greater than 0.70 are generally considered elevated; however, these reference values are derived from Doppler ultrasound measurements, and MRI-based RARI values may differ and require further validation. LS mean was estimated using a MMRM including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as Week 24 RARI minus the baseline RARI.
| Unitless | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Renal Artery Resistive Index (RARI) at Week 24 | 0.02 ± 0.008 | -0.02 ± 0.008 |
Peak systolic velocity (PSV) was the highest renal arterial blood flow velocity measured during systole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 PSV minus the baseline PSV.
| centimeters per second (cm/s) | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24 | 1.12 ± 1.790 | -2.12 ± 1.762 |
End-diastolic velocity (EDV) was the lowest renal arterial blood flow velocity measured during diastole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 EDV minus the baseline EDV.
| cm/s | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24 | -0.58 ± 0.442 | 0.33 ± 0.436 |
Total renal parenchyma volume was measured using magnetic resonance imaging by delineating the corresponding regions of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Total Renal Parenchyma Volume was calculated as: 100 × (Week 24 total renal parenchyma volume - baseline total renal parenchyma volume) / baseline total renal parenchyma volume.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24 | 0.19 ± 1.016 | -5.95 ± 1.053 |
Renal cortex volume was measured using magnetic resonance imaging by delineating the renal cortex region of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex Volume was calculated as: 100 × (Week 24 renal cortex volume - baseline renal cortex volume) / baseline renal cortex volume.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 24 | 0.40 ± 1.162 | -8.38 ± 1.206 |
Kidney parenchyma global perfusion was assessed as the mean renal blood flow per 100 g of kidney tissue measured by magnetic resonance imaging (MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Kidney Parenchyma Global Perfusion was calculated as: 100 × (Week 24 kidney parenchyma global perfusion - baseline kidney parenchyma global perfusion) / baseline kidney parenchyma global perfusion.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24 | 2.58 ± 2.971 | 8.09 ± 3.033 |
Renal cortex T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex T1 was calculated as: 100 × (Week 24 renal cortex T1 - baseline renal cortex T1) / baseline renal cortex T1.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 24 | 0.56 ± 0.481 | 2.82 ± 0.494 |
Renal medulla T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Medulla T1 was calculated as: 100 × (Week 24 renal medulla T1 - baseline renal medulla T1) / baseline renal medulla T1.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Renal Medulla T1 (MRI) at Week 24 | -0.09 ± 0.562 | -0.05 ± 0.580 |
Renal cortex R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex R2\* was calculated as:100 × (Week 24 renal cortex R2\* - baseline renal cortex R2\*) / baseline renal cortex R2\*
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Renal Cortex R2* at Week 24 | -1.94 ± 0.746 | -1.43 ± 0.764 |
Renal medulla R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction, with an unstructured covariance matrix. Percent change from baseline in Renal Medulla R2\* was calculated as:100 × (Week 24 renal medulla R2\* - baseline renal medulla R2\*) / baseline renal medulla R2\*.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Renal Medulla R2* at Week 24 | -1.78 ± 1.324 | -4.06 ± 1.343 |
Body weight was measured in kilograms using a calibrated electronic scale. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline was calculated as: 100 × (Week 24 body weight - baseline body weight) / baseline body weight. A negative value indicates a decrease in body weight.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in Body Weight at Week 24 | -0.05 ± 0.647 | -13.83 ± 0.642 |
Twenty-four-hour urinary albumin excretion (UAE) was derived from the 24-hour urine collection. Percent change from baseline at Week 24 was calculated relative to the baseline UAE value and was reported as %. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures on the log-transformed ratio to baseline, with log-transformed baseline value, treatment, and joint levels of stratification factors included as covariates. LS mean estimates and treatment comparisons were backtransformed and expressed as percent change from baseline. As pre-specified in the Statistical Analysis Plan, missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.
| Percent change | Placebo | Retatrutide |
|---|---|---|
| Percent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24 | 1.5 ± 9.17 | -36.0 ± 9.22 |
Twenty-four-hour urinary electrolyte excretion was derived from the 24-hour urine collection. Change from baseline was calculated as the Week 24 value minus the baseline value. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures, with baseline, treatment, and joint levels of stratification factors included as covariates. As pre-specified in Statistical Analysis Plan, Missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.
| milligrams/24hr (mg/24h) | Placebo | Retatrutide |
|---|---|---|
| Change From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24 | 116.3 ± 118.36 | -77.6 ± 22.89 |
Collected over Baseline up to end of follow-up (up to 28 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/69 (0%) | 6/69 (8.7%) | 6/69 (8.7%) |
| Retatrutide | 0/73 (0%) | 9/73 (12.3%) | 17/73 (23.3%) |
| Event | Placebo | Retatrutide |
|---|---|---|
| Prostate cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 1/42 |
| Acute myocardial infarctionCardiac disorders | 1/69 | 0/73 |
| Atrial fibrillationCardiac disorders | 1/69 | 0/73 |
| Cholecystitis acuteHepatobiliary disorders | 1/69 | 0/73 |
| Skin lacerationInjury, poisoning and procedural complications | 1/69 | 0/73 |
| Colorectal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 | 0/73 |
| Carotid artery stenosisNervous system disorders | 1/69 | 0/73 |
| Cerebrovascular accidentNervous system disorders | 1/69 | 0/73 |
| Knee arthroplastySurgical and medical procedures | 1/69 | 0/73 |
| HypertensionVascular disorders | 1/69 | 0/73 |
| Event | Placebo | Retatrutide |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/69 | 10/73 |
| NauseaGastrointestinal disorders | 4/69 | 7/73 |
| Decreased appetiteMetabolism and nutrition disorders | 0/69 | 6/73 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/69 | 4/73 |
| HypotensionVascular disorders | 3/69 | 4/73 |
All randomized participants.
| Age, Continuous(years) | Placebo | Retatrutide | Total |
|---|---|---|---|
| Mean | 65.4 ± 10.9 | 64.7 ± 10.3 | 65.1 ± 10.6 |
| Sex: Female, Male(Participants) | Placebo | Retatrutide | Total |
|---|---|---|---|
| Female | 34 | 32 | 66 |
| Male | 37 | 43 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Retatrutide | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 11 | 19 |
| Not Hispanic or Latino | 60 | 62 | 122 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | Retatrutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 8 | 7 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 16 | 24 |
| White | 52 | 50 | 102 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Placebo | Retatrutide | Total |
|---|---|---|---|
| Canada | 25 | 26 | 51 |
| Italy | 1 | 6 | 7 |
| Spain | 8 | 5 | 13 |
| United Kingdom | 6 | 4 | 10 |
| United States | 31 | 34 | 65 |
| Measured Glomerular Filtration Rate (mGFR)(mL/min/1.73 m²) | Placebo | Retatrutide | Total |
|---|---|---|---|
| Mean | 52.91 ± 15.606 | 51.50 ± 15.129 | 52.22 ± 15.323 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2023 to primary completion in Oct 2025, 26 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 26 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Retatrutide